following a full submission:
lenalidomide (Revlimid®) is accepted for use within NHSScotland.
Indication under review: In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 to 3a).
In a double-blind phase III study lenalidomide in combination with rituximab, compared with placebo plus rituximab, increased progression-free survival in adults with relapsed or refractory follicular lymphoma (Grade 1 to 3a).
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Medicine details
- Medicine name:
- lenalidomide (Revlimid)
- SMC ID:
- SMC2281
- Indication:
In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated Follicular Lymphoma (Grade 1 - 3a).
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 October 2020